← Back
$APLS All transactions

Apellis Pharmaceuticals, Inc.

A

$ Value

$0

Shares

55,986

Price

$0

Filed

Jan 30

Insider

Name

Watson David O.

Title

General Counsel

CIK

0001657719

Roles

Officer

Transaction Details

Transaction Date

2026-01-28

Code

A

Table

Non-Derivative

Ownership

Direct

Equity Swap

No

Shares After

144,517

Footnotes

This represents a Restricted Stock Unit award granted on January 28, 2026 that vest 25% annually over four years from grant date subject to continued service. | This represents a custodial account held by the reporting person for the sole benefit of his minor children. | The securities are held by The David O. Watson Irrevocable Trust of 2023. William Zorn is the trustee of The David O. Watson Irrevocable Trust of 2023. The reporting person disclaims beneficial ownership over the shares held by The David O. Watson Irrevocable Trust of 2023 except to the extent of his pecuniary interest therein. | The securities are held by The Watson Education Trust (the "Trust"), for which the reporting person serves as trustee. The reporting person disclaims beneficial ownership over the shares held by the Trust except to the extent of his pecuniary interest therein.

Filing Info

Accession No.

0001492422-26-000072

Form Type

4

Issuer CIK

0001492422

Watson David O.'s History

Date Ticker Type Value
2026-01-28 APLS A $0
2026-01-22 APLS $170K
2026-01-20 APLS $49K
2026-01-13 APLS $128K
2026-01-07 APLS M $13K
2026-01-07 APLS M $0
2025-12-16 APLS $122K
2025-11-17 APLS $100K
2025-10-16 APLS $126K
2025-09-16 APLS $122K

Other Insiders at APLS (90d)

Insider Bought Sold Last
Dolsten Mikael 2026-02-27
Deschatelets Pascal
Chief Scientific Officer
2026-01-28
Francois Cedric
Chief Executive Officer
2026-03-11
Sullivan Timothy Eugene
Chief Financial Officer
2026-04-17
O'Brien Stephanie Monaghan 2026-04-06
Nicholson Nur
Chief Technical Officer
2026-01-28
Chopas James George
VP/Chief Accounting Officer
2026-01-28
DeLong Mark Jeffrey
Chief Business & Strat Officer
$8K 2026-02-11
Boucher Kelley
Chief People Officer
2026-01-28
MELTZER LESLIE
Chief Research and Development
2026-01-28